LORI DWYER: Open Payments
NPI 1770604282 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,506 in 85 payments from 14 companies in 2025. Trend: 2023 $797 · 2024 $1,532 · 2025 $1,506
Food & beverage: $1,506
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $282 |
| Astellas Pharma US Inc | 10 | $238 |
| AstraZeneca Pharmaceuticals LP | 11 | $206 |
| Amgen Inc. | 20 | $196 |
| PFIZER INC. | 9 | $136 |
| Lilly USA, LLC | 5 | $106 |
| Abbott Laboratories | 4 | $92 |
| ABBVIE INC. | 5 | $89 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $32 |
Products named: Veozah, OTEZLA, AIRSUPRA, Ozempic, MOUNJARO, Rybelsus, FREESTYLE LIBRE 3, ELIQUIS.
Industry payments across PA — which companies pay providers there.
